Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment

Maecke, Helmut R; Reubi, Jean-Claude (2011). Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment. Journal of nuclear medicine, 52(6), pp. 841-4. New York, N.Y.: Society of Nuclear Medicine 10.2967/jnumed.110.084236

Full text not available from this repository.

Radiolabeled peptides have been an important class of compounds in radiopharmaceutical sciences and nuclear medicine for more than 20 years. Despite strong research efforts, only somatostatin-based radiopeptides have a real impact on patient care, diagnostically and therapeutically. [(111)In-diethylenetriaminepentaacetic acid(0)]octreotide is commercially available for imaging. Imaging was highly improved by the introduction of PET radionuclides such as (68)Ga, (64)Cu, and (18)F. Two peptides are successfully used in targeted radionuclide therapy when bound to DOTA and labeled with (90)Y and (177)Lu.

Item Type:	Journal Article (Original Article)
Division/Institute:	04 Faculty of Medicine > Service Sector > Institute of Pathology
UniBE Contributor:	Reubi-Kattenbusch, Jean-Claude
Subjects:	500 Science > 570 Life sciences; biology 600 Technology > 610 Medicine & health
ISSN:	0161-5505
Publisher:	Society of Nuclear Medicine
Language:	English
Submitter:	Factscience Import
Date Deposited:	04 Oct 2013 14:18
Last Modified:	05 Dec 2022 14:05
Publisher DOI:	10.2967/jnumed.110.084236
PubMed ID:	21571797
Web of Science ID:	000291030000010
URI:	https://boris.unibe.ch/id/eprint/5557 (FactScience: 210311)